狄诺塞麦推荐使用量是多少呢？

The US FDA approved denosumab (trade name: Xgeva) on November 18, 2010 to prevent bone-related events (SREs) in tumor patients whose cancer has metastasized and damaged bone. So-called bone-related events include pathological fractures caused by cancer, hypercalcemia, bone surgery or radiotherapy, and spinal cord compression. However, the approved population for denosumab does not include patients with multiple myeloma or other leukemias.

(1) Denosumab (denosumab) can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (5) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

There are currently no studies on the effectiveness and safety of this product in children, so denosumab (denosumab) is not recommended for children.

There is no need to adjust the dosage for the elderly and patients with renal insufficiency. For patients with severe renal insufficiency and those undergoing dialysis treatment, blood calcium monitoring should be carried out, and calcium and vitamin D supplementation should be paid attention to.

It is not yet clear whether denosumab (denosumab) can be excreted in breast milk. Breast-feeding women should weigh the importance of this product to them and choose to discontinue the drug or stop breastfeeding.

Pregnancy: Category C. There are no appropriate and well-controlled trials of denosumab in pregnant women. Denosumab should be used during pregnancy only if the potential benefits justifiably outweigh the potential risks to the fetus. Women who become pregnant during denosumab (denosumab) treatment are encouraged to enroll in the company's (denosumab) pregnancy monitoring program.